Tirzepatide: Side Effects & Safety
Part of the Tirzepatide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Common Side Effects
- Nausea (12–24%): Most common during titration, improves with continued use
- Diarrhea (12–17%): Mild to moderate, most common during dose increases
- Decreased appetite (5–11%)
- Vomiting (5–9%)
- Constipation (5–7%)
- Abdominal pain (5–7%)
- Injection site reactions (3–5%)
GI side effects are most common during the dose-escalation phase and typically diminish with continued treatment at a stable dose.
Serious Risks
- Pancreatitis: Cases reported in trials. Discontinue if suspected.
- Thyroid C-cell tumors: Boxed warning. GLP-1 agonists caused thyroid tumors in rodents. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
- Gallbladder events: Increased cholelithiasis (gallstones) likely related to rapid weight loss.
- Hypoglycemia: Low risk alone; increased with insulin or sulfonylureas.
For the complete overview, see the tirzepatide complete guide.